Author: GLP1-Consultant

With brand-name semaglutide medications like Ozempic and Wegovy often in short supply and costing over $1,000 per…

If you’re researching GLP-1 medications for weight loss, you’ve likely come across two names that dominate the…

Short answer There is no official “retatrutide price” yet because retatrutide is not FDA‑approved and is not…

Retatrutide has become a magnet for hype because early clinical trial results suggest very large weight loss…

Short answer Semaglutide is available now in the US as Wegovy (FDA-approved for chronic weight management) and…

Two names get mentioned a lot in the same breath: Tirzepatide (brand names Zepbound for chronic weight…

In the U.S., semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are FDA-approved GLP‑1–based medications used for weight management and/or type 2 diabetes, while retatrutide is an investigational triple-agonist (GIP/GLP‑1/glucagon) still in clinical trials. Trial averages suggest greater weight loss with tirzepatide than semaglutide 2.4 mg, and substantial weight loss with retatrutide in phase 2 research, but differences in FDA approval status, safety warnings, tolerability, and access often matter as much as average results.

Retatrutide is an investigational medication (not FDA-approved as of this writing). That means the only lawful way…

Retatrutide (also called LY3437943) is an investigational once-weekly injectable medicine being studied for obesity and related metabolic…